Fennec Pharmaceuticals Inc (FRX)

11.08
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    10.98/11.19
  • Day's Range:
    11.08 - 11.08
  • Type:Equity
  • Market:Canada
  • ISIN:CA31447P1009
  • CUSIP:31447P100

FRX Overview

Prev. Close
11
Day's Range
11.08-11.08
Revenue
210.24K
Open
11.08
52 wk Range
7.28-12.42
EPS
-0.87
Volume
0
Market Cap
281.75M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,247
P/E Ratio
-
Beta
0.01
1-Year Change
9.92%
Shares Outstanding
26,006,853
Next Earnings Date
Nov. 15, 2021
What is your sentiment on Fennec Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Fennec Pharmaceuticals Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellNeutralNeutralStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Buy
SummaryStrong SellStrong SellSellNeutralStrong Buy

Fennec Pharmaceuticals Inc Company Profile

Fennec Pharmaceuticals Inc Company Profile

Sector
Services
Employees
9
Market
Canada

Fennec Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical stage of development is PEDMARK. It announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.

Read More
  • No NEWS
    0
    • What time is FDA approval announcement?
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.